Actemra regulatory update

Roche disclosed in its 4Q10 earnings that last year it submitted regulatory applications in the U.S. and EU to expand the label of tocilizumab to include the treatment of systemic juvenile idiopathic arthritis. The humanized mAb against

Read the full 375 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE